Targeting KRAS mutations in lung cancer

Thomas Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, provides insights into the current landscape of targeting KRAS mutations in lung cancer treatment. He discusses the limited efficacy of existing drugs like sotorasib and adagrasib, noting modest response rates and potential toxicities. Newsom-Davis explores strategies to enhance treatment outcomes, including combining KRAS inhibitors with immunotherapy or other targeted agents to overcome resistance mechanisms. He highlights emerging data on pan-KRAS inhibitors, offering hope for addressing a broader spectrum of KRAS mutations beyond G12C. This interview took place at the BTOG 2024 congress in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.